Cilansetron shows efficacy in non-constipated irrirable bowel syndrome patients independent of the definition of the patient population by Rome I or Rome II

Caras, Steven; Krause, G; Biesheuvel, Egbert; Steinborn, Claus

doi:10.1016/s0016-5085(08)81077-3

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From early results of phase III studies, it appears that this drug is signifi cantly more effective than placebo in both men and women in relieving overall, as well as individual symptoms, including abdominal pain, diarrhea, frequency and urgency, in apparent contrast with the results obtained with alosetron, in which only women have benefi t [62] .…”

Section: -Htmentioning

confidence: 99%

See 1 more Smart Citation

Drugs Acting on Serotonin Receptors for the Treatment of Functional GI Disorders

Tonini

Pace

2006

Dig Dis

View full text Add to dashboard Cite

In the gut, serotonin (5-hydroxytryptamine: 5-HT) exerts a variety of effects on intrinsic enteric neurons, extrinsic afferents, enterocytes and smooth muscle cells, which are related to the expression of multiple 5-HT receptor types and subtypes regulating motility, vascular tone, secretion and perception. Agonists and antagonists at 5-HT receptors have gained access to the market for the two major variants of the irritable bowel syndrome (IBS), a functional disorder characterized by abdominal pain associated with diarrhea and/or constipation in the absence of any organic abnormality. Indeed, the 5-HT₃ receptor antagonist alosetron is available in the US market for the treatment of women with severe, diarrhea-predominant IBS (D-IBS) refractory to conventional therapy, whereas tegaserod, a partial 5-HT₄ receptor agonist, has been approved by the FDA and other regulatory agencies for the treatment of women with constipation-predominant IBS (C-IBS) or functional constipation. This review is mainly intended to discuss the role of non-neuronal (paracrine) and neuronal 5-HT in the pathophysiology of functional gastrointestinal disorders (FGIDs), such as IBS and functional dyspepsia, and the mechanisms through which drugs acting on 5-HT receptors regulate visceral motility, perception and secretion in these two conditions.

show abstract

Section: -Htmentioning

confidence: 99%

“…All of the cases of drug-induced ischemic colitis resolved without serious sequelae [64] . As for alosetron, the most commonly reported side effect of cilansetron was constipation, ranging from 19-40% for the various doses of the drug [62] .…”

Section: -Htmentioning

confidence: 99%

Drugs Acting on Serotonin Receptors for the Treatment of Functional GI Disorders

Tonini

Pace

2006

Dig Dis

View full text Add to dashboard Cite

show abstract

Cilansetron shows efficacy in non-constipated irrirable bowel syndrome patients independent of the definition of the patient population by Rome I or Rome II

Cited by 1 publication

References 0 publications

Drugs Acting on Serotonin Receptors for the Treatment of Functional GI Disorders

Drugs Acting on Serotonin Receptors for the Treatment of Functional GI Disorders

Contact Info

Product

Resources

About